. They also carry important phenotypic information about the clonal nature of tumors, which can help oncologists choose appropriate treatments . >
Science Sub-Journal: iPSC-derived cell therapy successfully repairs brain damage in mice | Yimai Meng broke the news
Time of Update: 2021-05-08
by stroke and dementia. The research paper was published in Science Translational Medicine, a sub-Journal of Science, entitled'Patient-derived glial enriched progenitors repair functional deficits due to white
Science Sub-Journal: Scientists find new ways to tackle eating disorders and obesity
Time of Update: 2021-05-08
regions, and showed sexual bimodal expression in some regions of mice and humans. The lack of MC3R produces various forms of anorexia bimorphism, similar to all aspects of human anorexia nervosa. However
Guidelines for the diagnosis and treatment of multiple myeloma in China (revised in 2020
Time of Update: 2021-05-08
Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally.
PLoS Pathogens: Discover new clues for mother-to-child transmission of HIV
Time of Update: 2021-05-08
The results of the study indicate that the circulating mother virus is resistant to bnAb- mediated neutralization, but not resistant to autologous plasma neutralization, which indicates an increased risk of mother-to-child transmission.
Nutrients: Can vitamin D be used to treat COVID-19
Time of Update: 2021-05-08
gov/33322317/" target="_blank" rel="noopener">High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study .
The average number of anti-tumor negotiation drugs in Chinese hospitals increased by 15
Time of Update: 2021-05-08
by the surveillance network in 2020 has increased by 15% over the previous year, and the average number of inpatients using these drugs An increase of 6%, while the average cost has dropped by 8%, and the average cost of some more expensive
IBD: Early combined immunosuppressive therapy can reduce the occurrence of complications in patients with Crohn's disease
Time of Update: 2021-05-07
com/ibdjournal/article-abstract/27/5/639/5863990?redirectedFrom=fulltext" target="_blank" rel="noopener">Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease.
IBD: vedolizumab combined with tacrolimus is more effective than vedolizumab alone in the treatment of colitis
Time of Update: 2021-05-07
In addition, compared with vedolizumab monotherapy, the combination of vedolizumab and tacrolimus is more effective in reducing the number of immune cells and increasing the efficacy of treatment.
FDA revokes emergency use authorization for Eli Lilly's new crown antibody drug
Time of Update: 2021-05-02
>
Editor: Wu Bin
>
As the new crown virus continues to mutate, the US pharmaceutical giant accidentally "lay the gun". On Friday, the US Food
Suoyuan Biotech's "first-in-class" new drug successfully achieved overseas authorization
Time of Update: 2021-05-02
On April 14, Suoyuan Biopharmaceuticals and Rumpus Therapeutics/Aytu Biopharma signed a global license agreement for the development of DB102 (enzastaurin) for the treatment of vascular Ehlers-Danglos syndrome (vEDS) and other rare genetic diseases.
China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States
Time of Update: 2021-04-28
The institute stated that this indicates that the safety and effectiveness of new coronavirus-specific antibody drugs with China's independent intellectual property rights have been recognized by the world.
PNAS: Studying donkeys helps understand the mechanism of HBV infection
Time of Update: 2021-04-28
of the disease. The research was led by DZIF scientists at Charité and Justus Liebig University Giessen in Berlin. March 19, 2021---According to a recent study, researchers found
Jianxin Force completes 625 million yuan A round of financing
Time of Update: 2021-04-27
;padding:0px;max-width:100%;box-sizing:border-box !important;overflow-wrap:break-word !important;letter-spacing:2px;font-size:14px;">Recently, Zhejiang Jianxin Force Pharmaceutical Co. , Ltd. ("Jianxin Force
Nat Neurosci | Zhou Zikai/Ji Minjun's team proposes potential treatment strategies for immune abnormal autism
Time of Update: 2021-04-23
and laboratory animal studies have shown that maternal immune activation (MIA) triggered by pathogens from the mother during pregnancy is an important risk factor for neuropsychiatric diseases such as autism in the offspring; at the same time, MIA has
Suoyuan Biotech's "first-in-class" new drug successfully achieved overseas authorization
Time of Update: 2021-04-23
On April 14, Suoyuan Biopharmaceuticals and Rumpus Therapeutics/Aytu Biopharma signed a global license agreement for the development of DB102 (enzastaurin) for the treatment of vascular Ehlers-Danglos syndrome (vEDS) and other rare genetic diseases.
President Interview|Ms. Song Qingchun, President and Founder of Spring Proswell, Accepts an Interview with "Pharma Tech Outlook
Time of Update: 2021-04-23
referred to as "Spring Proswell"), accepted a telephone interview with the international medical magazine "Pharma Tech Outlook". This is also the first time President Song Qingchun has been interviewed by the media. In this exclusive
